Multimodal Generative Al for Precision Health

Hoifung Poon

Microsoft Health Futures

Medicine Today Is Imprecise

IMPRECISION MEDICINE

For every person they do help (blue), the ten highest-grossing drugs in the United States fail to improve the conditions of between 3 and 24 people (red).



Based on published number needed to breat (NNT) figures. For a full list of references, see Supplementary information at gunature.com/4dr786.

Top 20 drugs 80% non-responders

Wasted 1/3 health spending \$1 Trillion / year

Cancer: Immunotherapy

Keytruda: immunotherapy blockbuster (\$25B, 2023) FDA approved for many cancer indications But only work for minority of patients **Wanted: Complex biomarker for better stratification** Insight Consumer Pharma, Payor, Regulator



Data Producer Provider, EHR Vendor

Real-World Evidence (RWE)

Real-world data (RWD) are the data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources.

Real-world evidence (RWE) is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of RWD



Population-scale free lunch

Multimodal Patient Journey



Multimodal Patient Journey



Multimodal Patient Journey



https://www.adventisthealthcare.com/living-well/the-blind-men-and-the-elephant/

Precision Health Is a Multimodal Generative Problem



t

Precision Health Is a Multimodal Generative Problem



Disease Progression



Treatment Response

f

Precision Health Is a Multimodal Generative Problem



Disease Progression



Treatment Response

Multimodal Patient Embedding



Disease Progression



Treatment Response





GenAl disruption: High-fidelity patient embedding



Population-Scale RWE \rightarrow "Emergent Capabilities"

The Curse of Multimodal Complexities

Structured data: discrete, ordinal, numerical, ...

Clinical notes: unstructured, noisy, ...

- Radiology: 2D X-ray \rightarrow 3D CT, MRI, ...
- Digital pathology: Gigapixel images (120K X 120K)
- Genomics: 30-gene panel \rightarrow 600-gene panel \rightarrow WGS
- Spatial transcriptomics: 500 genes \rightarrow 4000 genes \rightarrow WES

The Curse of Multimodal Complexities

Structured data: discrete, ordinal, numerical, ...

Clinical notes: unstructured, noisy, ...

Radiology: 2D X-ray \rightarrow 3D CT, MRI, ...

Digital pathology: Gigapixel images (120K X 120K)

Genomics: 30-gene panel \rightarrow 600-gene panel \rightarrow WGS

Spatial transcriptomics: 500 genes \rightarrow 4000 genes \rightarrow WES

Case Study: Immunotherapy

Given Keytruda cohort, find exceptional responder Need to model tumor microenvironment





https://en.wikipedia.org/wiki/Tumor-infiltrating_lymphocytes

Digital Pathology: Transformer blows up...



3cm x 3cm, $40x \rightarrow 120K x 120K$ pixels

16 x 16 patch: 56 million tokens

Compute: Billions of times more than web images



Dilated attention

nature

Explore content v About the journal v Publish with us v

nature > articles > article

Article Open access Published: 22 May 2024

A whole-slide foundation model for digital pathology from real-world data

Hanwen Xu, Naoto Usuyama, Jaspreet Bagga, Sheng Zhang, Rajesh Rao, Tristan Naumann, Cliff Wong, Zelalem Gero, Javier González, Yu Gu, Yanbo Xu, Mu Wei, Wenhui Wang, Shuming Ma, Furu Wei, Jianwei Yang, Chunyuan Li, Jianfeng Gao, Jaylen Rosemon, Tucker Bower, Soohee Lee, Roshanthi Weerasinghe, Bill J. Wright, Ari Robicsek, ... Hoifung Poon ☑ + Show authors

Nature 630, 181–188 (2024) Cite this article

65k Accesses | 284 Altmetric | Metrics



Providence



GigaPath: First Whole-Slide Digital Pathology Foundation Model 170K whole slides (1.3B image tiles)

https://aka.ms/gigapath

GigaPath: Monthly Downloads > 90K

Hugging Face Q Search models, datasets, users	Models	Datasets	Spaces	9 Posts	Docs	🚔 Solutions	Pricing	~≡	
 prov-gigapath/prov-gigapath Image Feature Extraction timm () PyTorch vision medical Model card Files and versions Community Settings 						:	Use	this model	~
Sated model You have been granted access to this model	∠ Edit model card	Downloads l 90,166	ast month			2	\sim	^	~
Prov-GigaPath									
A whole-slide foundation model for digital pathology from real-world data [Code] [Model] [Paper] [BibTeX]		Inferent Image Fe Inference AP	ature Extraction	n Des not yet sup	oport timm me	odels for this pipel	line type.		
Hanwen Xu*, Naoto Usuyama*, Jaspreet Bagga, Sheng Zhang, Rajesh Rao, Tristan Naumann, Cliff Wong, Zelalem Gero, Javier González, Yu Gu, Yanbo Xu, Mu Wei, Wenhui Wang, Shuming Ma, Furu Wei, Jianwei Yang, Chunyuan Li, Jianfeng Gao, Jaylen Rosemon, Tucker Bower, Soohee Lee, Roshanthi Weerasinghe, Bill J. Wright, Ari Robicsek, Brian Piening, Carlo Bifulco, Sheng Wang, Hoifung Poon (*Equal Contribution)									



Unimodal: Encoder / Decoder

Modality-Specific Self-Supervision



The Curse of Multimodal Complexities



Combinatorial Explosion



Multimodal Babel Tower

Text = Interlingua



Cross-Modal: Adapters



LLaVA-Med: General Recipe

Li*, Wong*, Zhang*, et al. LLaVA-Med: Training a Large Language-and-Vision Assistant in One Day. *NeurIPS 2023, Spotlight.*





Towards Generative Diagnostics





Patient Image







Image Parsing: Segmentation, Detection, Recognition

https://microsoft.github.io /BiomedParse/



Foundation Model: Nine Modalities





Universal Embedding

Patient





Intervention



Optimize clinical care Accelerate biomed discovery

Information Access Can Be Life or Death

Marty Tenenbaum

Late-stage melanoma (late 1990s) Initial prognosis: 6 months Saved by Phase III trial of Canvaxin



US: Less than 3% cancer patients enroll in trials 40% cancer trial failures due to insufficient patients New drug costs \$2-10 billion and takes 10+ years

US alone, 2M new cancer patients every year



Just-in-time clinical trial matching

	 Submit Studies v Data and API v Policy v About v 	My Saved Studies (0)-
Home > Search Results > Study Re	cord	
The U.S. gove Read our full day	rnment does not review or approve the safety and science of all studies listed on this wet hamer for details.	bsite. +
RECRUITING Cabozantinib in High Gra Cabozantinib in High Gra Clinical Tridespoy ID © NCT0441 Spensor © Wishington Universit Information provided by © Wast Last Update Posted © 2022-104	de Neuroendocrine Neoplasms 1629 School of Madicine Ington University School of Medicine (Responsible Party) 5	
	+ Expend all	content - Collapse all content
Study Details Res	earcher View No Results Posted Record History	
On this page		
Study Overview	Study Overview	
	Brief Summary	Study Start (Actual)
Contects and Locations		
Contacts and Locations Portrepation Cirterio	High grade neuroenclocrine neoplasm patients are treated with platinum doublets such as carboplatin	2020-11-24
Contacts and Locations Portropolon Criterio Study Plan	High grade neurosmolacrine neoplaam patients are treated with platinum doublets such as carboplatin and etoposide mimicking the current guidelines for small cell lang cancer (SCLC). Unfortunately, resumeous seconomous and most patients with metastatic disease succurring to it within a year. There is,	2020-11-24 Primary Completion (Estimated) .
Contempoten Collectors Portequilien Collecto Study Plan Collaboration and Investigators	High grade meananchacrime mexplarem partients are treated with platimum doublets such as cartoplatin and etoposide mimicking the current guidelines for small call harg cancer (SCLC). Unfortunately, recurrences are common and most patients with metastatic discore succords to this within a year. There is no extensive iterature or consensus on second- or third-line options (which include FOLFOX, FOLFIR).	2020-11-24 Primary Completion (Unimated) @ 2024-11-30
Connects and Learnings Portroportion Criteria Study Plan Collaborations and Investigators Publications	High goale neuroenskasine nexplarer patients are treated with platimar doublets such as carboplatin and elopsaide mimicking the current goaletimes for small call lang cancer (SCLC). Unfortunately, resurrences are common and most patients with metastatic disease succurb to it within a year. There is no extensive literature or consensus on second- or third-line options (which include FOLFOX, FOLFIRI, capecitable and temczolomido, taxanes or immunotherapy) and there is urgent need for better moments.	2020-11-24 Primary Completion (Exclosured) 2024-11-30 Study Completion (Estimated)
Coreates and Lacottices Post ceptition Cittlesia Study Plan Colliaborators and Investigators Publications Study Record Dates	High goade neuroanclachine neoptierm patients are treated with platimam doublets such as carboplatin and stoppaide minicking the current guidelines for small cell tang cancer (SCLC). Unfortunately, recurrences are common and most patients with metactatic disease succurib to it within a year. There is no extensive floarourse or consensus on second- or third-line options (which include FOLFOK, FOLFIR, capecitables and tenzolomide, taxanes or immunotherapy) and there is urgent need for better regiment.	2020-11-24 Primery Completion (Kelonated) ● 2024-11-30 Study Completion (Estimated) ● 2025-07-31
Constant and Locations Portropolion Criticia Study Plan Collisbonstons and Investigators Publications Study Record Dates None Information	High goade neuroanclachine neoptierm patients are treated with platimam doublets such as carboplatin and etoposide mimicking the current guidelines for small cell hang cancer (SCLC). Unfortunately, recurrences are common and most patients with metactatic disease succurits to it within a year. There is no entensive itsursure or concernus on second or third-line options (which include FOLFOX, FOLFIR), capecitable entenceionnide, taxanes or immunotherapy) and there is urgent need for better regimens. Official Thie Cabourninitio in High Cracke Neuroendocrine Neoptaires	2020-11-24 Primary Completion (Entimated) • 2024-11-30 Study Completion (Estimated) • 2025-07-31 Enrollmeter (Estimated) •
Connector and Laborators Portregation Oritoria Study Plan Collaborators and Investigators Publications Study Record Dates More Information	High goad neuroanchachne neopteam patients are treated with platinam doublets such as carboptatin and stoposide mimicking the current guidelines for small cell hang cancer (SCLC). Unfortunately, recurrences are common and most patients with metactatic disease succurb to it within a year. There is no extensive iterature or consensus on second- or third-line options (which include FOLFOK, FOLFIR), capacitable and temczolomido, taxanes or immunotherapy) and there is urgent need for better regimens. Official Title Cabcountinib in High Grade Neuroendoctine Neoplaams: Cadioxani nib in High Grade Neuroendoctine Neoplaams:	2020-11-24 Primary Completion (Kelmannel) ● 2024-11-30 8hady Completion (Estimated) ● 2025-07-31 Encollineer (Estimated) ● 32

olinia di Tala la mar

400K clinical trials at ct.gov Thousands of active cancer trials

Hoifung Poon, Microsoft Health Futures

ClinicalTrials.gov

Home > Search Results > Study Record

RECRUITING 3

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Information provided by Providence Health & Services (Responsible Party) Last Updated: May 6, 2022



Next: 51 hospitals, 950 clinics, 500 oncologists, 50,000 patients/year

Dr. Rom Leidner

Providence

Wong et al. "Scaling Clinical Trial Matching Using Large Language Model: A Case Study in Oncology", *MLHC, 2023*. The New York Times

Reprogrammed Cells Attack and Tame Deadly Cancer in One Woman

Another patient who had the same treatment did not survive. But the demonstration of the technique could help with other cancers.



Resources ~

ClinicalTrials.gov Identifier: NCT04520711

About ~



A colored scanning electron micrograph of pancreatic cancer cells. Steve Gschmeissner/Science Source



Real-World Evidence: In Silico Clinical Trial Simulation



TrialScope: In Silico Clinical Trial Simulation

Trial	Trial RCT			Simulation HR			
	HR	95%CI	HR	95%CI	C	Т	match?
FLAURA	0.63	(0.45, 0.88)	0.57	(0.43, 0.77)	255	169	√
			0.76	(0.61, 0.95)	458	347	
CHECKMATE057	0.73	(0.59, 0.89)	0.63	(0.46, 0.86)	109	136	~
			0.77	(0.64, 0.93)	304	413	
CHECKMATE078	0.68	(0.52, 0.9)	0.79	(0.60, 1.03)	140	198	√
			0.79	(0.65, 0.97)	305	415	
KEYNOTE010	0.71	(0.58, 0.88)	0.70	(0.56, 0.87)	187	539	~
			0.74	(0.62, 0.88)	332	1044	
OAK	0.73	(0.62, 0.87)	0.63	(0.33, 1.19)	129	33	~
			0.47	(0.32, 0.69)	345	88	
KEYNOTE024	0.63	(0.47, 0.86)	0.68	(0.5, 0.93)	104	524	~
			0.79	(0.61, 1.02)	250	1178	
STELLA	1.108	(0.27, 1.48)	1.10	(0.75, 1.61)	1507	54	√
			1.31	(1.00, 1.73)	4004	100	
NCT00130728	0.78	(0.79, 1.17)	0.87	(0.67, 1.14)	264	91	~
			1.12	(0.91, 1.37)	517	173	
CHECKMATE017	0.59	(0.44, 0.79)	0.87	(0.53, 1.43)	36	66	×
			0.77	(0.64, 0.93)	304	413	
EMPHASIS	?	?	0.76	(0.59, 0.97)	192	322	?
			0.77	(0.62, 0.94)	330	485	
NCT02604342	?	?	0.42	(0.23, 0.78)	1001	29	?
			0.52	(0.34, 0.82)	1742	53	

Gonzalez et al. "TrialScope: A Unifying Causal Framework for Scaling Real-World Evidence Generation with Biomedical Language Models", *arxiv 2311.01301*.

Providence







Hoifung Poon

Tristan Naumann

Cliff Wong

g Naoto Usuyama



Sheng Zhang



Zelalem Gero



Jass Bagga

Collaborators

Providence: Carlo Bifulco, Brian Piening, Roshanthi Weerasinghe, Rom Leidner

JnJ: Xiaoying Wu, Tommaso Mansi

U. Wash: Sheng Wang

USC: Muhao Chen

Stanford: Akshay Chaudhari

Microsoft: Jianfeng Gao, Javier Alvarez-Valle, Javier Gonzalez, Tao Qin, Tie-Yan Liu, Furu Wei, Mu Wei, Sam Preston, Emre Kiciman, Naveen Valluri, Paul Viozila, Matt Lungren, Harjinder Sandhu Interns: Maxim Grechkin, Ankur Parikh, Victoria Lin, Sheng Wang, Stephen Mayhew, Daniel Fried, Violet Peng, Hai Wang, Robin Jia, Matthew McDermott, Alexis Ross, Zelalem Gero, Sarthak Jain, Jenny Chen, Hunter Lang, Benedikt Boecking, Varsha Kishore, Jinfeng Xiao, Michelle Li, Wenxuan Zhou, Neha Hulkund, Risa Ueno, Peniel Argaw, Hanwen Xu, Juan Manuel Zambrano Chaves, Mars Huang, Yiqing Xie, Isabel Chien, Eduard Orakvin, Alicia Curth



Population-Scale RWE \rightarrow "Emergent Capabilities"